CoChat
Sign Up
Cited by 148Antifungal resistance and susceptibilityPharmacovigilance and Adverse Drug ReactionsFungal Infections and Studies

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

Sable, C.A., Nguyen, B‐Y T., Chodakewitz, J.A., DiNubile, M.J.·2002·Transplant Infectious Disease
DOI 10.1034/j.1399-3062.2002.01004.x
Open this paper in CoChat — free account

Abstract

Caspofungin acetate is the first member of the novel echinocandin class of antifungal drugs to be marketed in the United States. It has recently been approved for use in patients with invasive aspergillosis who are refractory to or intolerant of conventional therapy. Accordingly, its safety profile is particularly important to review. The safety and tolerability of caspofungin have been examined in 623 persons, including 295 patients who received >/= 50 mg/day for at least one week in clinical studies. In the 263 patients, given caspofungin in randomized double-blind active-control trials to date, there have been no serious clinical or laboratory drug-related adverse events; caspofungin was discontinued in only 2% of these patients because of drug-related adverse experiences. Caspofungin may have potentially important drug interactions with cyclosporine and tacrolimus.

Overview

Integrity signals

Registry

Crossref · 10.1034/j.1399-3062.2002.01004.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 6

  1. SableCA VillaneuvaA ArathoonE et al.A randomized double‐blind multicenter trial of MK‐0991 (L‐743872) versus amphotericin B (AMB) in the treatment ofCandidaesophagitis in adults.Presented at the 37th Interscience Conference on Antimicrobial Agents Chemotherapy.Toronto Ontario Canada October 1997: LB‐33.
  2. Stone JS, 1998, Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy
  3. Xu X, 1998, Disposition of MK‐0991, a potent antifungal agent, in rats with acute renal failure, Pharm Sci, 1, 463
  4. Stone JA, 2000, Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
  5. Stone JA, 2000, Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;
  6. Stone J, 2001, Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy;

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Venue
Transplant Infectious Disease
Publisher
Wiley
Published
2002-03
Volume
4
Issue
1
Pages
25-30
ISSN
  • 1398-2273 (ISSN-L)
  • 1399-3062
DOI
10.1034/j.1399-3062.2002.01004.x
OpenAlex
W2041457471
Cited by
148
References
5
Citations by year
2025: 4 · 2024: 2 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 7 · 2013: 4 · 2012: 7
FWCI
12.32
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 140 d)
Locations
  • Transplant Infectious Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords
caspofungin acetate, echinocandins, antifungal agents, invasive aspergillosis, drug safety, tolerability, adverse drug reactions, refractory fungal infection
MeSH terms
Caspofungin, Anti-Bacterial Agents, Antifungal Agents, Aspergillosis, Candidiasis, Double-Blind Method, Drug Tolerance, Fever, Headache, Humans, Mycoses, Peptides, Peptides, Cyclic, Phlebitis, Retrospective Studies, Randomized Controlled Trials as Topic, Immunocompromised Host, Drug Approval, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review